Our focus allows us to give enhanced attention to specific challenges in biochemical testing and accelerate product development and delivery.

The first and only platform in newborn screening for lysosomal storage disorders authorized by the FDA.

Innovative platform that operates on tiny droplets of blood to rapidly perform time critical tests in various distributed settings.

Related Content